JP2002206000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002206000A5 JP2002206000A5 JP2001352728A JP2001352728A JP2002206000A5 JP 2002206000 A5 JP2002206000 A5 JP 2002206000A5 JP 2001352728 A JP2001352728 A JP 2001352728A JP 2001352728 A JP2001352728 A JP 2001352728A JP 2002206000 A5 JP2002206000 A5 JP 2002206000A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- fusion protein
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016267 Leptin Human genes 0.000 claims description 4
- 108010092277 Leptin Proteins 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 102000049953 human LEP Human genes 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56173295A | 1995-11-22 | 1995-11-22 | |
| US08/561,732 | 1995-11-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Division JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002206000A JP2002206000A (ja) | 2002-07-23 |
| JP2002206000A5 true JP2002206000A5 (enExample) | 2007-04-05 |
| JP4227325B2 JP4227325B2 (ja) | 2009-02-18 |
Family
ID=24243198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Expired - Fee Related JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
| JP2001352728A Expired - Fee Related JP4227325B2 (ja) | 1995-11-22 | 2001-11-19 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Expired - Fee Related JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (3) | EP1285664B1 (enExample) |
| JP (2) | JP4173914B2 (enExample) |
| AT (2) | ATE259243T1 (enExample) |
| AU (3) | AU7607496A (enExample) |
| CA (2) | CA2236163A1 (enExample) |
| DE (2) | DE69638119D1 (enExample) |
| DK (1) | DK0866720T3 (enExample) |
| ES (2) | ES2217327T3 (enExample) |
| IL (2) | IL124442A0 (enExample) |
| MX (1) | MX9803992A (enExample) |
| NZ (3) | NZ512083A (enExample) |
| PT (1) | PT866720E (enExample) |
| SI (1) | SI0866720T1 (enExample) |
| WO (1) | WO1997018833A1 (enExample) |
| ZA (1) | ZA969605B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| CA2236163A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US5831017A (en) * | 1996-01-25 | 1998-11-03 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| EP0917469A1 (en) * | 1996-04-19 | 1999-05-26 | ZymoGenetics, Inc. | Methods for inducing bone formation |
| WO1998028414A1 (en) * | 1996-12-20 | 1998-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| EP1835030A1 (en) * | 1996-12-20 | 2007-09-19 | Amgen, Inc. | OB fusion protein compositions and methods |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| EP0950417A3 (en) | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
| WO1999053939A1 (en) * | 1998-04-20 | 1999-10-28 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis with leptin |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| AU1134000A (en) * | 1998-10-27 | 2000-05-15 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
| EP1151102B1 (en) * | 1999-02-12 | 2006-04-19 | Amgen Inc. | Glycosylated leptin compositions and related methods |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| ATE475094T1 (de) | 2001-10-22 | 2010-08-15 | Amgen Inc | Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| JP2008505119A (ja) * | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ，コーポレイション | 高分子−第ｉｘ因子部分の抱合体 |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| DK1814590T4 (da) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
| WO2008048691A2 (en) * | 2006-10-18 | 2008-04-24 | Amylin Pharmaceuticals, Inc. | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| MX349054B (es) | 2010-09-28 | 2017-07-07 | Aegerion Pharmaceuticals Inc | Leptinas altamente solubles. |
| CN111529535A (zh) | 2012-09-27 | 2020-08-14 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| DK3509624T3 (da) | 2016-09-12 | 2023-11-13 | Amryt Pharmaceuticals Inc | Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228925B (it) * | 1987-08-07 | 1991-07-10 | Eniricerche Spa | Procedimento per la preparazione dell'ormone della crescita umano |
| DK173142B1 (da) * | 1988-08-24 | 2000-02-07 | Natinco Nv | Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| DE4428146A1 (de) * | 1993-08-13 | 1995-02-16 | Putzmeister Maschf | Verfahren und Anordnung zur Oberflächenbearbeitung von Großobjekten |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| CA2236163A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| IL124831A0 (en) * | 1995-12-27 | 1999-01-26 | Genentech Inc | Ob protein derivatives having prolonged half-life |
| EP1835030A1 (en) * | 1996-12-20 | 2007-09-19 | Amgen, Inc. | OB fusion protein compositions and methods |
| IL132380A0 (en) * | 1997-04-17 | 2001-03-19 | Amgen Inc | Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods |
-
1996
- 1996-11-04 CA CA002236163A patent/CA2236163A1/en active Pending
- 1996-11-04 DE DE69638119T patent/DE69638119D1/de not_active Expired - Lifetime
- 1996-11-04 AU AU76074/96A patent/AU7607496A/en not_active Abandoned
- 1996-11-04 AT AT96938773T patent/ATE259243T1/de active
- 1996-11-04 EP EP02011474A patent/EP1285664B1/en not_active Expired - Lifetime
- 1996-11-04 EP EP98119160A patent/EP0956862A1/en not_active Withdrawn
- 1996-11-04 CA CA002358862A patent/CA2358862A1/en not_active Abandoned
- 1996-11-04 NZ NZ512083A patent/NZ512083A/xx not_active IP Right Cessation
- 1996-11-04 NZ NZ511617A patent/NZ511617A/en not_active IP Right Cessation
- 1996-11-04 JP JP51974597A patent/JP4173914B2/ja not_active Expired - Fee Related
- 1996-11-04 WO PCT/US1996/017718 patent/WO1997018833A1/en not_active Ceased
- 1996-11-04 DK DK96938773T patent/DK0866720T3/da active
- 1996-11-04 ES ES96938773T patent/ES2217327T3/es not_active Expired - Lifetime
- 1996-11-04 DE DE69631544T patent/DE69631544T2/de not_active Expired - Lifetime
- 1996-11-04 AT AT02011474T patent/ATE455554T1/de not_active IP Right Cessation
- 1996-11-04 EP EP96938773A patent/EP0866720B1/en not_active Expired - Lifetime
- 1996-11-04 NZ NZ527007A patent/NZ527007A/en not_active IP Right Cessation
- 1996-11-04 ES ES02011474T patent/ES2339846T3/es not_active Expired - Lifetime
- 1996-11-04 SI SI9630675T patent/SI0866720T1/xx unknown
- 1996-11-04 PT PT96938773T patent/PT866720E/pt unknown
- 1996-11-04 IL IL12444296A patent/IL124442A0/xx not_active IP Right Cessation
- 1996-11-15 ZA ZA969605A patent/ZA969605B/xx unknown
-
1998
- 1998-05-20 MX MX9803992A patent/MX9803992A/es not_active IP Right Cessation
-
1999
- 1999-01-05 IL IL127926A patent/IL127926A/en not_active IP Right Cessation
-
2000
- 2000-06-23 AU AU42652/00A patent/AU763755B2/en not_active Ceased
- 2000-06-23 AU AU42653/00A patent/AU763769B2/en not_active Ceased
-
2001
- 2001-11-19 JP JP2001352728A patent/JP4227325B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guichard et al. | Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. | |
| JP2018171063A5 (enExample) | ||
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| CA2251464A1 (en) | Non-dendritic backbone peptide carrier | |
| WO2006076410A3 (en) | Li-key/antigenic epitope hybrid peptide vaccines | |
| WO1991008220A1 (en) | A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines | |
| NZ512083A (en) | Methods of increasing lean tissue mass using OB protein compositions | |
| ATE478089T1 (de) | Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen | |
| JP2005502332A5 (enExample) | ||
| US7122193B1 (en) | Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis | |
| US6245904B1 (en) | Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific T-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide | |
| CA2522329A1 (en) | Inhibitors of coronavirus | |
| CN118891059A (zh) | 嵌合多肽 | |
| Löwenadler et al. | Enhanced immunogenicity of recombinant peptide fusions containing multiple copies of a heterologous T helper epitope | |
| RU2001127439A (ru) | Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом | |
| Park et al. | Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope | |
| TW200838558A (en) | New immunomodulating oligopeptides | |
| Astori et al. | Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic | |
| DK1719520T3 (en) | ANTIGENE EPITOPES OF REGULATION PROTEIN OF VIRULENS FACTOR IN STAPHYLOCOCCUS AUREUS AND MIMOTOPES THEREOF AND USE | |
| JPS60501360A (ja) | 大腸菌由来の熱安定性エンテロトキシンポリペプチドの合成品及びその多量体 | |
| Leist et al. | Antibodies to synthetic polypeptides corresponding to hydrophilic regions of human interferon gamma | |
| Jakab et al. | Synthesis and antibody recognition of cyclic epitope peptides, together with their dimer and conjugated derivatives based on residues 9− 22 of herpes simplex virus type 1 glycoprotein D | |
| KR890009972A (ko) | 펩티드, 이의 제조방법, 항체를 수득하기 위한 이의 용도, 및 인간 혈액중의 pai 1 활성을 억제하기 위한 항체의 용도 | |
| JP2004509846A (ja) | 肝炎ｃ型ウイルスコンジュゲート | |
| US6764689B1 (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |